- Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
- Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
- Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
More ▼
Key statistics
As of last trade, Phathom Pharmaceuticals Inc (PHAT:NSQ) traded at 10.34, 70.49% above the 52 week low of 6.07 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.35 |
---|---|
High | 10.63 |
Low | 10.15 |
Bid | 10.32 |
Offer | 10.35 |
Previous close | 10.35 |
Average volume | 502.49k |
---|---|
Shares outstanding | 58.54m |
Free float | 52.89m |
P/E (TTM) | -- |
Market cap | 605.84m USD |
EPS (TTM) | -4.41 USD |
Data delayed at least 15 minutes, as of May 23 2024 19:26 BST.
More ▼